source
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin diseaseMerck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
- Reporter visits Shanghai to see China’s fast‑growing biotech sector as Chinese‑designed drugs make up about half of the global pipelineA STAT+ correspondent traveled to Shanghai to get a first‑hand view of the rapid expansion of China’s biotech industry. The piece describes the bustling research environment and the growing number…